Next Article in Journal
Cannabinoids for Therapeutic Use in Atherosclerosis
Previous Article in Journal
Results of the “Menarini Prize for Echocardiography 2005”
 
 
Cardiovascular Medicine is published by MDPI from Volume 28 Issue 1 (2025). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Editores Medicorum Helveticorum (EMH).
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Angio-SealTM Vascular Closure Device: An Evaluation of Cost Effectiveness †

by
Ursula Schoenenberger
,
Peter Ammann
,
Micha Maeder
and
Hans Rickli
*
Department of Internal Medicine, Division of Cardiology, Kantonsspital, CH-9007 St.Gallen, Switzerland
*
Author to whom correspondence should be addressed.
This work has been supported in part by: St. Jude Medical, Inc., Wettingen, Switzerland.
Cardiovasc. Med. 2006, 9(7), 257; https://doi.org/10.4414/cvm.2006.01189
Submission received: 30 May 2006 / Revised: 30 June 2006 / Accepted: 30 July 2006 / Published: 30 August 2006

Abstract

Background: Optimal management of the vascular access site is crucial to early ambulation after percutaneous coronary intervention (PCI) and has thus major impact on the costs of the procedure. In this study, we assessed the cost-effectiveness, safety, and patient comfort of the Angio-SealTM Hemostatic Puncture Closing Device in PCI patients. Methods: In a single-centre trial, 43 patients were prospectively randomised to either immediate arterial sheath removal with Angio- Seal™ access site closure (Angio-Seal group; n = 21), or sheath removal 4 hours after elective PCI followed by manual compression (MC group; n = 22). In the Angio-Seal group, patients were ambulated 4 hours after PCI if haemostasis was achieved. In the MC group, patients were ambulated the day after PCI. Results: The time to achieve haemostasis was significantly shorter (Angio-Seal™: 2.0 ± 1.0 vs MC: 22.5 ± 4.6 min; p <0.001), and back pain after the intervention was significantly lower (Angio-Seal™: pain score 1.5 ± 1.4 vs MC: 6.0 ± 3.0; p <0.001) in the Angio-Seal group. Haemostasis was successful in all patients and no major complications occurred. The Angio- Seal™ device allowed earlier ambulation (Angio- Seal™: 4.0 ± 2.0 vs MC: 18.5 ± 2.7 hours; p <0.001). Total direct costs were significantly lower in the Angio-Seal™ compared to the MC group (514 Euro saved per patient, representing a reduction of 54%) due to reductions of nursing time (Angio-Seal™: 7.1 ± 2.5 vs MC: 9.4 ± 2.6 hours; p = 0.006) and time of the interventional physician (Angio-Seal™: 5.4 ± 7.9 vs MC: 22.5 ± 4.6 min; p <0.001). Conclusions: Compared to MC the use of the Angio-Seal™ is associated with cost saving due to shorter time to haemostasis and thus earlier ambulation and hospital discharge, as well decreased personnel and infrastructural demands. In addition, the use of Angio-Seal™ is safe and increases patient comfort.
Keywords: access site management; interventional cardiology; puncture sealants; complications; coronary interventions access site management; interventional cardiology; puncture sealants; complications; coronary interventions

Share and Cite

MDPI and ACS Style

Schoenenberger, U.; Ammann, P.; Maeder, M.; Rickli, H. Angio-SealTM Vascular Closure Device: An Evaluation of Cost Effectiveness. Cardiovasc. Med. 2006, 9, 257. https://doi.org/10.4414/cvm.2006.01189

AMA Style

Schoenenberger U, Ammann P, Maeder M, Rickli H. Angio-SealTM Vascular Closure Device: An Evaluation of Cost Effectiveness. Cardiovascular Medicine. 2006; 9(7):257. https://doi.org/10.4414/cvm.2006.01189

Chicago/Turabian Style

Schoenenberger, Ursula, Peter Ammann, Micha Maeder, and Hans Rickli. 2006. "Angio-SealTM Vascular Closure Device: An Evaluation of Cost Effectiveness" Cardiovascular Medicine 9, no. 7: 257. https://doi.org/10.4414/cvm.2006.01189

APA Style

Schoenenberger, U., Ammann, P., Maeder, M., & Rickli, H. (2006). Angio-SealTM Vascular Closure Device: An Evaluation of Cost Effectiveness. Cardiovascular Medicine, 9(7), 257. https://doi.org/10.4414/cvm.2006.01189

Article Metrics

Back to TopTop